Lower serum levels of granzyme B and homozygous and heterozygous variants of GZMB rs8192917 are associated with poor prognosis and worse clinical outcomes with PD-1 blockade in patients with NSCLC, highlighting the importance of considering T cell response-related mutations in predicting NSCLC prognosis and response to immunotherapy (Hurkmans et al., 2020). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.